How much funding has Ankyra Therapeutics raised?

Ankyra Therapeutics has raised $45.0M in total funding, most recently a Series B round.

When was Ankyra Therapeutics founded?

Ankyra Therapeutics was founded in 2019.

Where is Ankyra Therapeutics headquartered?

Ankyra Therapeutics is headquartered in Boston, Massachusetts, United States.

What industry is Ankyra Therapeutics in?

Ankyra Therapeutics operates in Biotech, Pharmaceutical.

How many employees does Ankyra Therapeutics have?

Ankyra Therapeutics has 11-50 employees.

Ankyra Therapeutics

Boston, United States · Founded 2019 · $45.0M raised

Biotech

Pharmaceutical

Headquarters: Boston, Massachusetts
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: ankyratx.com
Total Funding: $45.0M
Last Round: $45.0M Series BNov 2021
Rounds: 1

About

Ankyra Therapeutics is a Boston-based clinical-stage biotechnology company developing cancer immunotherapies built on its Anchored Immunotherapy platform, which localizes potent cytokines within tumors to prime a systemic adaptive immune response while limiting systemic toxicity. Its lead candidate, ANK-101, combines a modified IL-12 cytokine with an aluminum hydroxide scaffold (Alhydrogel) that retains the drug at the injection site after intratumoral administration. The approach aims to create durable anti-tumor immune activation across solid tumors.

Summary

Ankyra Therapeutics is a Biotech company based in Boston, United States, founded in 2019. It has raised $45.0M in total across 1 round, most recently a $45.0M Series B round in Nov 2021.

LinkedIn X (Twitter)